TrialPediatric blood & cancer2024

A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614).

Emily Greengard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.